Tardive dyskinesia Nervous System Diseases Drug-induced dystonia
Conditions
Interventions
1. Group 1 has high cannabidiol extract Nabidiolex® (CBD) (300mg) administered twice a day for six weeks as an adjunctive treatment alongside their usual antipsychotic medication. CBD will be administ
Sponsors
Stellenbosch University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adults 18 years and older 2. Currently meets the ICD-10 diagnosis of a psychotic disorder, verified with the Mini International Neuropsychiatric Interview (MINI-PLUS) questionnaire. 3. Currently meets the clinical diagnosis of tardive dyskinesia confirmed with the Abnormal Involuntary Movement Scale (AIMS) 4. Patients should currently be receiving treatment for a psychotic disorder and should be on either the atypical or conventional antipsychotics 5. Patient gives informed consent
Exclusion criteria
Exclusion criteria: 1. ICD-10 diagnosis of an organic mental illness, substance misuse disorder or a seizure disorder 2. Serious or chronic physical illness 3. Known severe drug allergies or hypersensitivity to CBD
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in symptoms of tardive dyskinesia measured using the Abnormal Involuntary Movement Scale (AIMS). Assessments will be conducted at baseline, 2 weeks, 4 weeks, 6 weeks (post-treatment) and at 12 weeks follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Side effects of CBD will be periodically assessed with the Glasgow check list and reported at each assessment 2. Improvement in psychotic symptoms | — |
Countries
Nigeria
Outcome results
None listed